Found 81 clinical trials
Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions
This trial is designed as a prospective, multi-centre, open-label, single-arm, phase II study. Oral Premalignant Lesions (OPL) may be considered the equilibrium phase of the immunoediting concept, i.e. a dynamic process between the tumour cells and the immune system including surveillance by the immune system or tumour progression. Thus, an …
- 8 views
- 27 Jan, 2021
- 5 locations
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically. In the last 2 years, immune check points inhibitors (mainly Programmed Death (PD)-1 inhibitors) were approved for metastatic/recurrent HNC. The favorable toxicity profile and …
- 55 views
- 15 Feb, 2022
- 1 location
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with Lenvatinib
- 0 views
- 12 Aug, 2022
- 10 locations
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants
- 0 views
- 12 Jul, 2022
- 8 locations
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread to other places in the body
- 0 views
- 12 Aug, 2022
- 77 locations
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have
- 0 views
- 31 Oct, 2021
- 46 locations
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)
administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
- 31 views
- 14 Jul, 2022
- 44 locations
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
- 21 views
- 12 Jul, 2022
- 35 locations
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (IMAGINE)
with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune system attack the
- 4 views
- 03 May, 2022
- 341 locations
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
) + Vinorelbine (Navelbine) Group B: Trastuzumab + Vinorelbine + Avelumab Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
- 30 views
- 21 Jul, 2022
- 16 locations